Internal Medicine, Hematology & Oncology · Battle Creek, MI
NPI
1346765724
Since 2017
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
300 North Ave
Battle Creek, MI, 49017
Phone (269) 245-8660
Groups this clinician bills Medicare through
Medicare paid, 2024
$918K
53,645 services
Medicare patients, 2024
319
Average age 77
Drug cost, 2024
$1.6M
470 prescriptions
Company payments, 2025
$1,150
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Calvin Abro was code J1439 (injection, ferric carboxymaltose, 1 mg), 18,750 times for 14 patients. In total Calvin Abro billed 53,645 services in 112 codes, and Medicare paid $918K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 18,750 | 14 | $0.86 | $16K |
| 85025 Blood Count | Office | 520 | 188 | $7.57 | $3,935 |
| 36415 Venipuncture Blood Collection | Office | 501 | 185 | $8.63 | $4,325 |
| 80053 Clinical Chemistry | Office | 296 | 150 | $10.32 | $3,054 |
| 99214 Office E&M - Established | Office | 189 | 105 | $98.06 | $19K |
| 99213 Office E&M - Established | Office | 176 | 98 | $68.88 | $12K |
| 96413 Chemotherapy Administration | Office | 93 | 14 | $102.06 | $9,492 |
| 96372 Injection Administration | Office | 92 | 13 | $11.35 | $1,044 |
| 82728 Clinical Chemistry | Office | 79 | 58 | $13.21 | $1,043 |
| 96367 Intravenous Infusion, Hydration | Office | 72 | 11 | $22.26 | $1,603 |
| 99232 Hospital E&M - Subsequent | Facility | 67 | 45 | $63.42 | $4,249 |
| 99205 Office E&M - New | Office | 58 | 58 | $153.62 | $8,910 |
| 99215 Office E&M - Established | Office | 58 | 40 | $130.00 | $7,540 |
| 82607 Clinical Chemistry | Office | 54 | 45 | $14.54 | $785 |
| 99204 Office E&M - New | Office | 54 | 54 | $112.54 | $6,077 |
By year: 2023 $126K for 12,447 services; 2024 $918K for 53,645 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 520 | 188 | $7.57 | $3,935 |
| 36415 Venipuncture Blood Collection | 501 | 185 | $8.63 | $4,325 |
| 80053 Clinical Chemistry | 296 | 150 | $10.32 | $3,054 |
| 82728 Clinical Chemistry | 79 | 58 | $13.21 | $1,043 |
| 82607 Clinical Chemistry | 54 | 45 | $14.54 | $785 |
| 83615 Clinical Chemistry | 37 | 28 | $5.92 | $219 |
| 82746 Clinical Chemistry | 37 | 34 | $14.06 | $520 |
| 83735 Clinical Chemistry | 33 | 15 | $6.57 | $217 |
| 84100 Clinical Chemistry | 15 | 14 | $4.65 | $69.75 |
Medicare prescription drug claims, 2024
In 2024, the drug Calvin Abro prescribed most often to Medicare patients was Anastrozole, with 35 prescriptions and refills. In total Calvin Abro wrote 470 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 35 | 85 | 13 | $870 |
| Eliquis Apixaban | 35 | 50 | 11 | $29K |
| Tamoxifen Citrate Generic | 32 | 87 | 11 | $980 |
| Udenyca Autoinjector Pegfilgrastim-Cbqv | 22 | 22 | Under 11 | $91K |
| Letrozole Generic | 22 | 61 | Under 11 | $552 |
| Brukinsa Zanubrutinib | 21 | 21 | Under 11 | $303K |
| Jakafi Ruxolitinib Phosphate | 19 | 19 | Under 11 | $329K |
| Imatinib Mesylate Generic | 15 | 17 | Under 11 | $3,646 |
| Imbruvica Ibrutinib | 15 | 15 | Under 11 | $248K |
| Hydroxyurea Generic | 15 | 38 | Under 11 | $507 |
| Ondansetron Odt Ondansetron | 15 | 15 | 11 | $334 |
| Exemestane Generic | 15 | 45 | Under 11 | $4,523 |
| Acyclovir Generic | 12 | 26 | Under 11 | $126 |
| Libtayo Cemiplimab-Rwlc | 12 | 12 | Under 11 | $118K |
| Prednisone Generic | 11 | 17 | Under 11 | $40.71 |
Brand drugs: 193 claims; generic drugs: 277 claims; opioid claims: 12.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Calvin Abro $1,150 ($1,150 in general payments such as food, travel and fees) from 28 companies. The largest payer was Tempus AI, Inc with $184.
| Company | Payments | Amount |
|---|---|---|
| Tempus AI, Inc TEM | 4 | $184 |
| Incyte Corporation INCY | 4 | $157 |
| Abbvie Inc. ABBV | 6 | $100 |
| Merck Sharp & Dohme LLC MRK | 3 | $82.89 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $75.45 |
| Genzyme Corporation SNY | 2 | $43.01 |
| Genentech USA, Inc. ROG.SW | 2 | $38.33 |
| GlaxoSmithKline, LLC. GSK | 2 | $37.6 |
| Janssen Biotech, Inc. JNJ | 2 | $33.26 |
| Adc Therapeutics America, Inc. | 1 | $28.19 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.